Atera Launch Ignites 10x Genomics Surge | Business and Finance News

10x Genomics delivered a strong Q2 with $151M in revenue, boosted by a $1.6M one-time settlement with Takara—though core revenue rose 3% year-over-year. The real star? Their new Atera platform, which customers are raving about and ordering in droves for its unprecedented throughput, flexibility, and sensitivity. Existing products like Chromium consumables and Xenium spatial tech remain robust, while the acquisition of Proteintech Genomics bolsters protein measurement capabilities and expands Atera’s potential. With multi-omics adoption surging and new whole blood workflows enabling bigger studies, 10x is positioning itself as the cornerstone of next-gen biological discovery—and possibly reshaping entire markets. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/ce980e15ba0cb414